Association between the major histocompatibility complex and clinical response to infliximab therapy in patients with Behçet uveitis.
Association between the major histocompatibility complex and clinical response to infliximab therapy in patients with Behçet uveitis.
复制标题
Beh 患者主要组织相容性复合物与英夫利昔单抗治疗临床反应之间的关联
DOI：
10.1007/s10384-015-0404-2
复制
发表时间：
2015
期刊：
影响因子：
2.4
通讯作者：
Tsuneoka H.
中科院分区：
文献类型：
--
作者：
Kuroyanagi K;Sakai T;Kohno H;Okano K;Akiyama G;Aoyagi R;Inaba M;Tsuneoka H.
PurposeOur的目的是调查是否主要组织相容性复合体（MHC）多态性与英夫利昔单抗治疗反应在日本患者白塞葡萄膜炎（BU）。MethodsWe回顾性分析了24例（17名男性和7名女性）英夫利昔单抗治疗BU。其中10例为HLA A*2601，9例为HLA B*5101。两组的治疗反应水平进行了比较的基础上，眼部攻击和白塞病眼部攻击评分24（BOS 24）超过24 months的treatment.ResultsMean频率的眼部攻击在13-18和19-24个月后开始治疗的显着较高的thehLAA * 2601组（P= 0.0392和0.0177，分别）。在HLA A* 2601组中，第1-6、7-12、13-18和19-24个月的平均BOS 24 -6 M值也显著更高（分别为P= 0.0459、0.0150、0.0394和0.0178）。HLA A* 2601组中有8名患者需要缩短输注间隔，而HLA B* 5101组中只有1名患者需要缩短输注间隔。白塞病相关的不良事件发生在HLA A* 2601组的8名患者和HLA B* 5101组的2名患者中。HLA A* 2601组有4例患者发生非眼部不良事件，而HLA B* 5101组无患者发生。结论虽然HLA A26组和HLA B51组眼部发作评分较基线的平均变化相似，但HLA-A26组在英夫利昔单抗治疗眼/眼外受累时病程更严重。这些数据表明，对英夫利西单抗治疗的日本BU患者的反应部分是由于HLA复合体中的遗传决定因素。
PurposeOur aim was to investigate whether major histocompatibility complex (MHC) polymorphisms are associated with response to infliximab therapy in Japanese patients with Behçet uveitis (BU).MethodsWe retrospectively reviewed 24 patients (17 men and seven women) treated with infliximab for BU. Of them, ten patients were genotyped asHLA A*2601, and nine asHLA B*5101. Therapeutic response levels in the two groups were compared based on ocular attacks and the Behçet disease ocular attack score 24 (BOS24) over 24 months of treatment.ResultsMean frequencies of ocular attacks at 13–18 and 19–24 months after the start of treatment were significantly higher in theHLA A*2601group (P= 0.0392 and 0.0177, respectively). Mean BOS24-6 M values for months 1–6, 7–12, 13–18, and 19–24 were also significantly higher in theHLA A*2601group (P= 0.0459, 0.0150, 0.0394, and 0.0178, respectively). Shortening of the infusion interval was required in eight patients in theHLA A*2601group but in one only in theHLA B*5101group. Behçet-disease-related adverse events occurred in eight patients in theHLA A*2601group and two in theHLA B*5101group. Nonocular adverse events occurred in four patients in theHLA A*2601group and none in theHLA B*5101group.ConclusionsAlthough mean change from baseline in the number of ocular attack scores in theHLA A26andHLA B51groups seemed to be similar, theHLA-A26group had a more severe disease course under infliximab therapy for ocular/extraocular involvement. These data suggest that response to infliximab therapy in Japanese patients with BU is partly due to genetic determinants in the HLA complex.